Why we should use tools to evaluate osteoporosis risk? Olivier Bruyère (ULG)
Role of biochemical assessments in the management of osteoporosis. Etienne Cavalier (ULiège) Slides Belgian Menopause society avril 2022
Bisphosphonates vs. denosumab: Advantages and risks. Charlotte Verroken (UGent) Bisphosphonates vs. denosumab
MHT and SERMS for osteoporosis: do they still have a place? Serge Rozenberg (ULB-VUB) BMS osteoporosis 30.4.22 (1)
Satellite symposium UCB Romososumab: Results of trials, positioning and indications Evelien Gielen